Status:
COMPLETED
Protocol for Women at Increased Risk of Developing Breast Cancer
Lead Sponsor:
Carol Fabian, MD
Collaborating Sponsors:
Susan G. Komen Breast Cancer Foundation
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
Detailed Description
A blind randomized study of celecoxib in women at high risk of developing breast cancer. Subjects are to take twelve months of drug/placebo. At baseline and after twelve months subjects will have a ra...
Eligibility Criteria
Inclusion
- women who have a high risk of breast cancer
- older than 18 years
Exclusion
- anticoagulants
- marked breast tenderness
- pregnant or within twelve months of breast feeding/childbirth
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00291694
Start Date
April 1 2003
End Date
December 1 2009
Last Update
November 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160